Key result
Trial provides no reported quantitative hemodynamic results for ARB and SGLT2i combination therapy.
Why the study?
The kidney hemodynamic effects of angiotensin receptor blockade, sodium-glucose cotransporter-2 inhibition alone, and their combination in people with type 2 diabetes were not well characterized.
Does the combination of Angiotensin Receptor Blockade and Sodium-Glucose Cotransporter-2 Inhibition improve kidney hemodynamic effects in people with Type 2 Diabetes?
RCT
Crossover
Does the combination of Angiotensin Receptor Blockade and Sodium-Glucose Cotransporter-2 Inhibition improve kidney hemodynamic effects in people with Type 2 Diabetes?
Answers are grounded in this paper and cite their sources.
Randomized crossover trial evaluates kidney hemodynamic effects in type 2 diabetes, highlighting combined impacts of SGLT2 inhibition and angiotensin receptor blockade.
Funding Information: R.A.S., A.C.H., C.M.M., F.G., E.J.H., M.M.K., and J.A.J. report no conflicts. D.H.vR. has acted as a consultant for and received honoraria from Boehringer Ingelheim-Eli Lilly Alliance, Merck, Sanofi, and AstraZeneca, and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Merck. All honoraria are paid to his employer (Amsterdam University Medical Centers, location VUMC). D.J.T. reports grants from ZONMW and Chiesi Pharmaceuticals, as well as fees to his institution from ZONMW and PurelMS. H.J.L.H. has received research support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen, as well as fees to his institution for his participation on advisory boards from Merck, Mitsubishi Tanabe, Janssen, and Mundipharma; for consulting from AbbVie, Retrophin, Boehringer Ingelheim, and Novo Nordisk; and for participation in steering committees from Janssen, Gilead, Bayer, Chinook, and CSL Pharma.
No takes yet. Share an insight, caveat, or question.
Scholtes et al. (2022) conducted an RCT in Type 2 Diabetes. Angiotensin Receptor Blockade and Sodium-Glucose Cotransporter-2 Inhibition was evaluated on Kidney Hemodynamic Effects.
Synapse has enriched 10 related papers. Consider them for comparative context: